Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M312663200 on April 26, 2004

J. Biol. Chem., Vol. 279, Issue 27, 27994-27999, July 2, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/27/27994    most recent
M312663200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomas, S. K.
Right arrow Articles by Ross, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, S. K.
Right arrow Articles by Ross, R. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Nestin Is a Potential Mediator of Malignancy in Human Neuroblastoma Cells*

Sharon K. Thomas{ddagger}§, Conrad A. Messam¶, Barbara A. Spengler{ddagger}, June L. Biedler{ddagger}, and Robert A. Ross{ddagger}||

From the {ddagger}Laboratory of Neurobiology, Department of Biological Sciences, Fordham University, Bronx, New York 10458 and the Department of Neuroscience, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Received for publication, November 19, 2003 , and in revised form, April 23, 2004.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Amplification of the N-myc proto-oncogene signifies aggressive behavior in human neuroblastoma. Likewise, overexpression of the intermediate filament nestin, a neuroectodermal stem cell marker, is linked to increased aggressiveness in several nervous system tumors. We investigated the interaction of these two proteins in human neuroblastoma cells. Neuroblastic cell variants with high levels of N-Myc protein have significantly higher nestin protein levels than non-amplified cell lines, suggesting that the transcription factor N-Myc may regulate nestin expression. Stable transfection of a nestin antisense sequence into neuroblastic, N-myc-amplified, LA1–55n cells results in a 2-fold reduction in nestin protein without altering N-Myc expression. However, cell functions attributed to N-Myc (growth rate, anchorage-independent growth, and motility) all decrease significantly. Transfection studies that modulate N-Myc levels also result in commensurate changes in nestin mRNA and protein amounts as well as in cell proliferation and motility. Thus, nestin appears to be downstream of and regulated by N-Myc. Gel mobility shift assays show that N-Myc binds specifically to E-box sequences in the regulatory second intron of the nestin gene and nuclear run-off studies show that increases in N-Myc protein up-regulate nestin transcription rate. Subcellular fractionation and immunoblot studies indicate that nestin is present in the nucleus as well as in the cytoplasm of neuroblastoma cell lines. Finally, DNA cross-linking experiments show that nestin binds DNA in N-myc-amplified N-type cell lines. Thus, nestin may be one mediator of N-myc-associated tumor aggressiveness of human neuroblastoma.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Neuroblastoma is one of the most common neonatal solid tumors and remains a significant cause of death in young children. The proto-oncogene N-myc is influential in the pathology of this cancer; children with tumors containing single copy N-myc (per haploid genome) often have a favorable prognosis, whereas amplification and/or overexpression is strongly associated with metastasis, rapid disease progression, and a high rate of mortality (1). The N-myc gene encodes a nuclear phosphoprotein containing several distinct domains: a stretch of basic amino acids followed by basic helix-loop-helix-leucine zipper motifs involved in DNA binding and protein dimerization (2). N-Myc protein regulates gene expression at the transcriptional level by dimerizing with itself or other helix-loop-helix proteins and this complex, in turn, binds to DNA E-box sequences (e.g. CACGTG) of regulated genes (3, 4). Microarray analysis has shown that N-Myc regulates genes involved in growth, cell cycle, signaling, and adhesion (5). N-Myc protein expression has also been shown to play a role in cell proliferation and migration, as well as in maintenance of a committed, but less differentiated, cell state (6, 7). The exact mechanism of action of this transcription factor remains to be determined.

A second protein present in embryonic neuroectodermal cells is the intermediate filament (IF)1 nestin. IFs function in organizing the cytoskeleton (8), but they also have been implicated in cell signaling, organogenesis, and cell metabolism (9). Nestin, a marker of multipotent neuroectodermal precursor cells, is expressed in a cell-cycle-dependent manner and is down-regulated as neuroepithelial stem cells cease division and differentiate along their respective neural or glial lineages (10, 11). Similar to N-Myc, tumor aggressiveness has been associated with elevated nestin levels in some tumors (12). For instance, in primitive neuroectodermal tumors, elevated nestin characterizes the most malignant cell type (13). Also, nestin protein is elevated in the infiltrating parts of highly metastatic human glioblastomas and astrocytomas (13–16) and has been proposed to play a role in tumor invasion in melanomas (17).

Because both N-Myc and nestin have been implicated in the pathogenesis of several tumors of the nervous system, the present study examined the relationship between these two proteins in human neuroblastoma N-type cells. Specifically, we sought to determine whether nestin might be a downstream effector through which N-Myc influences malignancy in human neuroblastoma.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Tissue Culture—The human neuroblastoma cell lines and clones included in this study have been previously described (18–21). Cells were cultured according to published methods (22). Growth rates were determined by previously described methods (21).

Western Blot Analysis—Total cell protein homogenates were prepared by the method of Ikegaki et al. (23). Nuclear and cytoplasmic fractions were isolated as previously described (22). Western blot procedures have been published (22, 24). Primary antibodies included polyclonal antibodies to nestin (331b), homing cell adhesion molecule (HCAM) (Santa Cruz Biotechnology, Santa Cruz, CA), secretogranin II (gift of Dr. Jonathan G. Scammell, Department of South Alabama College of Medicine, Mobile, AL), tissue plasminogen activator (tPA) (ICN Pharmaceuticals, Inc., Aurora, OH), and vimentin (Chemicon International, Temecula, CA) and monoclonal antibodies to neurofilaments (NFs) 70 and 160, chromogranin A, {beta}-tubulin, and actin (clone C4) (Roche Applied Science). Following incubation with horseradish peroxidase-conjugated secondary antibodies (Roche Applied Science), protein-bound antibody was detected by chemiluminescence (ECL, Amersham Biosciences). Protein amounts were quantified by scanning densitometry and the relative amount compared with actin.

Isolation of mRNA and Northern Blot Analysis—Poly(A)+ RNA was isolated from cells in exponential growth phase with oligo(dT) cellulose (Collaborative Research, Boston, MA). Northern blots were performed as previously described (22) with 2–4 µg of mRNA and 32P-labeled probe to the fourth exon of the nestin gene. Expression levels, determined by scanning densitometry of resulting radioautographs, were compared with those of {lambda}-actin or glyceraldehyde-3-phosphate dehydrogenase.

Nestin and N-Myc Transfections—Antisense nestin transfections were performed with a 265-bp fragment from the fourth exon of the nestin gene generated by PCR (primers Xba-nestin 5':5'-GATCTCTAGACACTGGAGTCTGTGGAA-3' and Kpn-Nestin 3':5'-GATCGGTACCGGTCCTTCTCCACCGTATCTT-3') and inserted in an antisense orientation into the pBactNeo vector (25). Antisense N-myc transfections used a 2-kb N-myc cDNA inserted in the antisense direction into a pCI vector (Promega, Madison, WI) (a gift of Dr. Naohiko Ikegaki, Children's Hospital of Philadelphia, Philadelphia, PA). LA1–55n cells were stably transfected using LipofectAMINE Plus (Invitrogen) and selected with 500 µg/ml Geneticin (G418). N-myc non-amplified SH-SY5Y cells were transfected with a pCI vector containing a 2-kb N-myc cDNA in the sense direction (also a gift of Dr. Ikegaki) and selected with 100 µg/ml of G418. The concentration of G418 was lower than that used for LA1–55n because of the marked sensitivity of SH-SY5Y to antibiotic.

S Phase Fraction Determination—The percentage of cells in S phase was determined by a modification of the method of Freshney (26). Stably transfected antisense nestin and control LA1–55n clones were seeded into chamber slides and cultured for 6 days; resulting non-synchronized, exponential growth phase cultures were pulse-labeled for 30 min with 10–4 M BrdUrd. After fixing with methanol:acetic acid (3:1) and washing with 10% trichloroacetic acid to remove unincorporated nucleoside, DNA was denatured with 0.1 N NaOH because the antibody to BrdUrd only recognizes single-stranded DNA. Cells were immunostained by standard techniques with mouse anti-BrdUrd monoclonal antibody (Oncogene Research Products, La Jolla, CA), biotinylated secondary antibody, and the Vector ABC Elite staining kit (Vector Labs, Burlingame, CA). Nuclei were counterstained with hematoxylin. The percentage of cells containing BrdUrd was determined by counting four to five contiguous fields (250x) in four different areas for each clone.

Motility Invasion Assay—In vitro cell motility and invasivity were measured by the method of Albini et al. (27) using Matrigel Invasion Chambers (BD Biosciences, Bedford, MA) according the methods of the manufacturer, except that twenty thousand cells were seeded into chamber inserts. Cell motility is expressed as the number of cells that migrated through an uncoated membrane. The degree of cell invasivity is expressed as the percentage of cells migrating through an ECM-coated membrane compared with that through an uncoated membrane.

Transformation Assay—The malignant potentials of vector-, antisense-, and non-transfected LA1–55n cells were determined in soft agar experiments (21). Colony-forming efficiency in the presence or absence of G418 is expressed as the percentage of the cell inoculum (2000 cells) that formed colonies. Experiments were performed in triplicate.

Gel Mobility Shift Assay—A 32P-labeled 540-bp double-stranded fragment from the second intron of the nestin gene, containing two E-box sequences, was generated by PCR using primers 5'-CCTGGAGGTGGCCACGTACAG-3' and 5'-CATCAGAGGAGTCTCGCCCCATGACAT-3'. Binding was assayed by the method of Classon et al. (28). DNA-protein complexes were resolved by electrophoresis through a 4% non-denaturing polyacrylamide gel. Control experiments included: 1) use of DNA probe in which both E-box sequences were mutated using the primers: 5'-CCTGGAGGTGGCCACGTACAGGCCCAAGACGAGCCCTGT-3' and 5'-GCTGGGCCAATATGGGGCAACTGCATC-3', 2) addition of either non-radioactive probe or a nonspecific competitor (i.e. a DNA fragment from the glyceraldehyde-3-phosphate dehydrogenase gene) in molar excess before adding 32P-labeled probe, 3) addition of increasing amounts of protein homogenate (15–90 µg) to reaction mixtures, and 4) preincubation of cell extracts with antibody specific for N-Myc (sc-142) or p53 (sc-126) (Santa Cruz Biotechnology) and removal of antigen-antibody complexes with protein G-Sepharose (Amersham Biosciences).

DNA-Protein Cross-linking—DNA-protein cross-linking studies were performed following the procedure of Ferraro et al. (29) and Spencer et al. (9). Proteins eluted from the DNA were analyzed by Western blotting. Control experiments utilized cells incubated without cisplatin.

Nuclear Run-off—Nuclear run-off experiments were modified from those of Spengler et al. (21) and Hildebrandt and Neufer (30). Nuclei from vector- and N-myc-transfected SH-SY5Y cells were isolated with Nonidet P-40 lysis buffer (22) and stored in glycerol at –80 °C. Transcription was allowed to proceed for 15 min at 37 °C, followed by removal of endogenous DNA and protein with DNase I and proteases and purification of RNA. Quantitation of the nascent RNA transcripts was performed by reverse transcription-PCR using the Superscript II RNase H-system (Invitrogen). PCR was performed on diluted reverse transcription product with primers specific to nestin: 5'-ACTGGAGTCTGTGGAAGTGA-3' and 5'-TCAGCTCCCGCAGCAGACTCACC-3' and to {lambda}-actin: 5'-GGTTACGGCAGCACTTTT-3' and 5'-CAACGGACTCAGCAGATGCGT-3'. Amplification products were separated on 2% agarose gels. Ethidium bromide-stained bands were quantified from photographs using scanning densitometry. Controls consisted of nuclei in which the run-off reactions were omitted. Values are expressed relative to {lambda}-actin.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Relationship between N-myc Amplification/Overexpression and Nestin Protein Levels—Increased amounts of both N-Myc and nestin have been correlated with increased aggressiveness and malignancy of neuroectodermal tumors. In human neuroblastoma, N-Myc is overexpressed in tumorigenic N-type cells (21). We therefore investigated the coexpression of these two proteins in nine human neuroblastoma N-type cell lines by immunoblot analysis. Cells were collected during logarithmic growth phase as nestin is down-regulated in stationary growth phase (31). As seen in Table I and Fig. 1, nestin protein levels are ~2-fold higher in the cell lines that amplify and/or overexpress N-myc (mean = 23.5 ± 1.0) compared with the group of cell lines that does not (mean = 11.0 ± 0.5). NBL-S, a cell line that has an elevated N-Myc steady-state protein level but does not amplify the gene (32), has nestin levels similar to amplified cell lines (data not shown), thus indicating that higher amounts of nestin correlate specifically with N-Myc protein levels rather than with amplification per se.


View this table:
[in this window]
[in a new window]
  		TABLE I
Nestin protein amount in N-myc-amplified and non-amplified human neuroblastoma N-type cells

Nestin amounts are expressed in units; each value represents the mean ± S.E. from 5–7 experiments.

 



View larger version (33K):
[in this window]
[in a new window]
  		FIG. 1.
Immunoblot analysis of nestin and actin protein in N-myc-amplified and non-amplified human neuroblastoma N-type cell lines. Lanes and cell lines: 1, SMS-LHN; 2, SH-SY5Y; 3, SH-EP15; 4, LA-N-6; 5, BE(2)-M17; 6, LA1–55n; 7, NBL-Wn; 8, SMS-KAN. Note that N-myc-amplified lines have significantly more protein than non-amplified lines.

 
Effect of Change in Nestin Expression on Cell Phenotype and Growth Rate—Because elevated nestin levels have been implicated in tumor malignancy, change in nestin expression might affect the malignant behavior of neuroblastoma. To directly address this possibility, stable nestin antisense-transfectant clones were generated from the N-myc-amplified LA1–55n clonal cell line. Western blot analysis confirmed that antisense transfectants have significant, 1.6- or 1.8-fold lower levels of nestin protein compared with vector-transfected cells or non-transfected LA1–55n cells, respectively (Table II).


View this table:
[in this window]
[in a new window]
  		TABLE II
Amounts of nestin, N-Myc, and marker proteins in nestin antisense-transfected and control cells

Each value represents the mean ± S.E. of data from ten vector-transfected control (Ctrl) LA1–55n clonal cell lines or six nestin antisense-transfected (NesAs) LA1–55n clonal cell lines.

 
The reduction in nestin amount has no effect on cell morphology or adhesion to the substrate. Similarly, levels of neuronal marker proteins NF 70 and 160, secretogranin II, and chromogranin A do not differ among the three groups (Table II and data not shown). None of the lines or transfectants expresses S-type marker proteins vimentin and HCAM either before or after transfection (data not shown). Thus, cells with reduced nestin levels remain neuroblastic. More importantly, N-Myc protein amounts remain unchanged between LA1–55n cells and the vector- or nestin antisense-transfected cells (Table II).

Because both nestin and N-Myc appear to play a role in cell proliferation (31, 33–35), we determined the effect of reduced nestin levels on the growth rates of transfectants compared with parental LA1–55n cells. Whereas there are no significant differences in mean population doubling times between LA1–55n cells (24.9 ± 0.3 h) and vector-transfected clones (mean = 23.3 ± 0.6 h), mean doubling time for antisense clones is increased significantly 1.6-fold, to 40.6 ± 2.5 h (p < 0.001) (Table III).


View this table:
[in this window]
[in a new window]
  		TABLE III
Decrease in nestin protein in antisense transfectants affects cell malignancy and growth rate

Each value represents the mean ± S.E. of either 3–4 experiments (nestin protein amount), 1–3 experiments (doubling time), or 2–4 experiments (colony-forming efficiencies) in 4–6 clones.

 
As an independent measure of cell growth rate, we determined the percentage of cells in S phase by BrdUrd incorporation. Clones of two nestin antisense transfectants and two vector-transfected controls were cultured for 6 days to reduce incidence of subculture-induced cell synchrony and, while still in exponential growth phase, pulsed with BrdUrd. Stable nestin antisense transfectants had a 1.7-fold lower percentage of cells in S phase (20.6 ± 3.5%) compared with vector-transfected controls (33.7 ± 2.6%) (p < 0.01), numbers consistent with the differences observed for population doubling times. The reduction in growth rate demonstrated by both methods is not a consequence of the action of another N-myc-regulated protein as levels of the oncoprotein do not change.

Nestin Influences Malignant Potential and Metastasis—To assess malignant potential, vector- and nestin antisense-transfected cells were assayed for anchorage-independent growth ability in clonogenic soft agar assays. As shown in Table III, both LA1–55n and the vector-transfected control cells are transformed, with mean plating efficiencies of 12.6% and 12.3%, respectively. By contrast, nestin antisense transfectants show a marked, nearly 5-fold, reduction in colony-forming ability (2.6%). Because N-Myc protein levels are the same in these three groups, changes in nestin appear responsible for changes associated with malignancy.

Cell lines and transfectants were also tested for their ability to digest and migrate through an artificial extracellular matrix (ECM). These assays show that N-type cells with more nestin protein are more migratory (Fig. 2). Thus, N-type cell lines with lower levels of nestin migrate more slowly than their nestin-rich counterparts (Fig. 2A). Similarly, although most vector-transfected and parental LA1–55n cells migrate through non-coated control insert membranes (92 and 100%, respectively), antisense-transfected cells display a greater than 3-fold reduction in migratory ability (Table IV and Fig. 2B). However, cell invasivity, i.e. the ability to digest and move through Matrigel ECM-coated membrane compared with non-coated inserts, is not altered (Table IV). The ability of cells to digest the ECM was assessed independently by measuring the amount of tissue plasminogen activator protein (tPA), the primary serine protease involved in neuroblastoma metastasis (36). Results showed that tPA levels do not differ among the three groups (Table IV). Therefore, reduction in nestin amount impairs the motility of neuroblasts, but not their ability to digest the ECM.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 2.
Cell motility correlates with nestin expression in human neuroblastoma cell lines (A) and transfectants (B). A, LA1–55n ({blacksquare}), other N-myc-amplified cell lines () (NBL-Wn, BE(2)-M17, SMS-KAN), and non-amplified cell lines ({circ}) (SH-SY5Y, LA-N-6, and SMS-LHN). B, parental LA1–55n cells ({blacksquare}), two vector-transfected control clones ({circ}), and two nestin-antisense clones ({blacktriangleup}).

 


View this table:
[in this window]
[in a new window]
  		TABLE IV
Nestin influences cell motility but not cell invasiveness

Each value represents the mean ± S.E. of four to six experiments for three LA1–55n cultures, four vector- (Ctrl) and six antisense nestin (NesAs)-transfected clones.

 
Effect of Changes in N-Myc Expression on Nestin Expression, Cell Growth, and Malignant Potential—From the above studies, it is clear that several of the cell functions previously attributed to N-Myc, e.g. proliferation and migration, are altered in nestin antisense-transfectants even though N-Myc levels are unchanged. Therefore, we propose that, in N-type neuroblastoma cells, nestin is regulated by and is a down-stream target of N-Myc. To test the first part of this hypothesis, cellular N-Myc levels were modulated in two transfection experiments. In the first, N-myc-amplified LA1–55n N-type cells were transfected with vector with or without an N-myc cDNA inserted in the antisense orientation and clones generated. Vector-transfected clones have similar amounts of N-myc mRNA and protein compared with parental LA1–55n cells, whereas N-myc antisense-transfected clones have >2-fold lower amounts of the N-Myc mRNA and protein (Fig. 3A and Table V). Nestin mRNA and protein levels in the antisense N-myc transfectants are decreased significantly, nearly 2- and 5-fold, respectively (Fig. 3A and Table V). In the second experiment, the N-myc non-amplified N-type cell line, SH-SY5Y, was stably transfected with an expression vector containing an N-myc cDNA and clones selected with 100 µg/ml G418. Low level selection was necessitated by the marked sensitivity of this cell line to G418. Analysis indicated an almost 2-fold increase in both N-Myc and nestin protein and in nestin mRNA levels in the sense transfectants compared with vector-transfected controls (Table V). Thus, modulation of expression of N-Myc alters expression of nestin. Similar to the antisense nestin transfectants, antisense N-myc transfectants exhibit longer doubling times (41.6 ± 3.5 h), lower motility, and unchanged invasivity compared with vector transfectants and LA1–55n cells (Table VI). Conversely, sense N-myc transfectants grow more rapidly and display increased motility compared with parental SH-SY5Y cells or vector transfectants.



View larger version (36K):
[in this window]
[in a new window]
  		FIG. 3.
A, expression of N-myc and nestin mRNA in vector- and antisense-N-myc ({alpha}N-myc)-transfected LA1–55n cells analyzed by RT-PCR. B, in vitro transcription of nestin and {lambda}-actin in vector- and N-myc senseransfected SH-SY5Y cells. Note that both N-myc and nestin levels decrease in the antisense transfectants compared with {lambda}-actin control.

 


View this table:
[in this window]
[in a new window]
  		TABLE V
N-myc expression and nestin expression and transcription rates in N-myc sense and antisense transfectants

Values represent the mean ± S.E. of protein amount, normalized to actin, or steady-state amount of nestin mRNA, normalized to glyceraldehyde-3-phosphate dehydrogenase, in 3–4 vector- and sense- or antisense-transfected clones, expressed relative to vector control. The rate of transcription is normalized to glyceraldehyde-3-phosphate dehydrogenase and expressed relative to vector.

 


View this table:
[in this window]
[in a new window]
  		TABLE VI
Modulation of N-myc expression alters cell doubling time, motility, and invasivity

Each value represents the mean ± S.E. of 2–4 independent experiments in LA1–55n or SH-SY5Y cell lines, 2–3 vector-transfected controls (Ctrl), or 3 sense- or antisense (As)-N-myc-transfected clones.

 
N-Myc Binds to E-boxes in the Second Intron of the Nestin Gene and Regulates Its Transcription—As an initial approach to showing that N-Myc might regulate nestin in N-type cells, we investigated whether N-Myc can bind to the nestin gene in vitro in gel mobility shift assays. Studies have shown that N-Myc alters the rates of transcription of specific genes by binding to E-box regions within regulatory elements (37). The second intron of the human nestin gene is regulatory (38) and the 5' end of this intron contains two E-box elements, one canonical (CACGTG) and one non-canonical (CACGAG). Homogenates from N-Myc-overexpressing LA1–55n cells, when incubated for 10–15 min with a 540-bp DNA probe containing both E-box sequences (Fig. 4, lane 2), form two more slowly migrating complexes whereas homogenates from SH-EP1 cells, which lack N-Myc, do not (data not shown). To confirm that N-Myc protein in the lysate is causing the shift, LA1–55n lysate was preincubated with either anti-N-Myc or anti-p53 antibody and the antibody-antigen complexes removed (see "Experimental Procedures"). Preincubation with N-Myc, but not p53, antibody abrogates the shift (Fig. 4, lane 4 and data not shown). The specificity of N-Myc binding to the E-boxes in the nestin second intron was assessed by three additional methods. In competition experiments, addition of increasing amounts of unlabeled nestin intronic DNA proportionately decreases the amount of labeled DNA in the complexes (Fig. 4, lane 3); addition of a nonspecific unlabeled glyceraldehyde-3-phosphate dehydrogenase DNA does not (data not shown). Second, in titration experiments, the intensity of the label in the complexes is proportional to the amount of LA1–55n homogenate added (data not shown). Finally, incubation of LA1–55n homogenate with a nestin intronic DNA in which both E-boxes were mutated does not result in a mobility shift (Fig. 4, lane 5). These studies strongly suggest that N-Myc regulates nestin expression. The exact composition of the two DNA-protein complexes, a consistent finding in these experiments, has not been determined.



View larger version (69K):
[in this window]
[in a new window]
  		FIG. 4.
Gel mobility shift analysis of binding of N-myc to nestin E-box sequences. Lanes and content: 1, DNA probe alone; 2, DNA probe plus LA1–55n lysate; 3, DNA probe plus LA1–55n lysate plus 50 mM excess cold probe; 4, DNA probe plus LA1–55n lysate preincubated with N-Myc antibodies; 5, LA1–55n lysate incubated with mutated DNA probe.

 
To directly assess whether N-Myc is affecting nestin transcription rate, nuclear run-offs were performed on N-myc- and vector-transfected SH-SY5Y cells. As shown in Fig. 3B and Table V, there is a nearly 2-fold increase in nestin transcription rate in N-myc-transfected SH-SY5Y cells compared with vector control. Thus, N-Myc directly regulates nestin gene expression.

The Intermediate Filament Protein Nestin Binds Nuclear DNA—As an intermediate filament, nestin is instrumental in organizing the cytoskeleton and thus its altered expression could affect cell proliferation and motility. Less obvious is how nestin amount influences malignancy. In addition to their roles as components of the cytoskeleton, some intermediate filaments are present in the nucleus where they appear to bind and regulate gene expression (9, 39, 40). One possibility is that nestin could function in a similar fashion in human neuroblastoma. Subcellular fractionation and Western blot analyses show that nestin protein is present in both the cytoplasm and the nucleus of N-type neuroblastoma cell lines, LA1–55n and KCN-69n (41; data not shown).

To confirm the presence of nestin in the nucleus, cross-linking experiments were performed using the chemotherapeutic agent cisplatin (29). Cisplatin forms adducts with DNA dinucleotides d(pGpG) and induces intrastrand cross-links; proteins in close proximity to DNA will also be cross-linked. DNA-protein complexes were isolated, and the cross-linked proteins were eluted and analyzed via Western blot analysis. As seen in Fig. 5, nestin protein is in close proximity to DNA only in N-myc-amplified neuroblastoma cell lines; cisplatin does not cross-link nestin to DNA in N-myc non-amplified cell lines such as CB-JMN and SH-SY5Y. Thus, cell lines that have more N-Myc protein also have higher nestin protein levels, and it is in these cells that nestin is present in the nucleus and appears to interact with DNA.



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 5.
Western blot of nuclear proteins probed with a nestin antibody. Lanes and cell lines: 1, CB-JMN; 2, SK-N-ER; 3, SH-SY5Y; 4, BE(2)-M17; 5, LA1–55n; 6, SK-N-LP; 7, SK-N-JD. Cells were incubated with (+) or without (–) cisplatin.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Nestin is expressed in cells that are in a pluripotent, mitotic, and migratory state. The present studies demonstrate a novel role for the intermediate filament nestin in human N-type neuroblastoma cells and strongly suggest that the effects of N-Myc on cell proliferation and motility may be mediated, in part, by nestin. Experimental reduction in nestin protein amount does not alter N-Myc levels, but it dramatically lengthens the population doubling time (by 60%), decreases anchorage-independent growth (by 5-fold), and reduces cell motility (by 3-fold). Experimental reduction in N-Myc levels in the same cells has similar results: concomitant reductions in nestin mRNA and protein as well as decreases in growth rate and motility. Conversely, when N-Myc is transfected into an N-myc non-amplified cell line, nestin expression increases, as does invasivity, motility, and growth rate. Together, these observations provide evidence that regulation of nestin expression could be one mechanism by which N-Myc influences neuroblastoma growth, malignancy, and metastasis. The mechanism by which nestin effects these changes is currently under investigation.

Traditionally, IFs are thought to stabilize and support cells and to organize cells into tissues. However, some cytoskeletal proteins have been reported to be involved in nuclear activities as well. It has been shown that IFs are present in the nucleus where they bind specific DNA sequences (42–44) and can influence DNA organization and chromatin structure (40). Some IFs are implicated in inducing a more malignant phenotype; overexpression of vimentin or keratins in melanomas or breast carcinomas, respectively, leads to an augmentation of tumor cell motility and invasiveness (42). Other studies show that the nuclear/cytoplasmic intermediate filament profile is significantly altered in breast carcinoma cells (39, 40).

So it is of considerable interest that, in addition to an extensive nestin cytoplasmic network, Western analysis shows that nestin is present in the nucleus of N-myc-amplified N-type neuroblastoma cell lines. As shown by the DNA-cross-linking studies, the intermediate filament protein nestin interacts with nuclear DNA only in human neuroblastoma cells that amplify the N-myc gene. Thus, nestin may function to regulate expression of as yet unidentified genes in N-myc-overexpressing cells and tumors. Moreover, because nestin appears to be an effector of N-Myc, it may provide a novel target for clinical intervention. Elucidation of new therapeutic targets such as nestin may improve the survival chances of children with the worst prognoses.


   FOOTNOTES
 
* This research was supported by NCI, National Institutes of Health Grant CA77593 and the GRATIS Fund (to R. A. R.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Present address: Dept. of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461. Back

|| To whom correspondence should be addressed: Dept. of Biological Sciences, Fordham University, 441 East Fordham Rd., Bronx, NY 10458. Tel.: 718-817-3654; Fax: 718-817-3616; E-mail: rross{at}fordham.edu.

1 The abbreviations used are: IF, intermediate filament; NF 70, 70-kDa neurofilament; NF 160, 160-kDa neurofilament protein; HCAM, homing cell adhesion molecule; tPA, tissue plasminogen activator; ECM, extracellular matrix; G418, Geneticin; BrdUrd, 5-bromo-2'-deoxyuridine. Back



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Norris, M. D., Burkhart, C. A., Marshall, G. M., Weiss, W. A., and Haber, M. (2000) Med. Pediatr. Oncol. 35, 585–589[CrossRef][Medline] [Order article via Infotrieve]
  2. Luscher, B., and Eisenman, R. N. (1990) Genes Dev. 4, 2025–2035[Free Full Text]
  3. Blackwood, E. M., and Eisenman, R. N. (1991) Science 215, 1211–1217
  4. Torres, R., Schreiber-Agus, N., Morgenbessaer, S. D., and DePinho, R. A. (1992) Curr. Opin. Cell Biol. 4, 468–474[CrossRef][Medline] [Order article via Infotrieve]
  5. Boon, K., Caron, H. N., VanAsperen, R., Valentijn, L., Hermus, M. C., VanSluis, P., Roobeek, I., Weis, I., Voûte, P. A., Schwab, M., and Versteeg, R. (2001) EMBO J. 20, 1383–1393[CrossRef][Medline] [Order article via Infotrieve]
  6. Wakamatsu, Y., Watanabe, Y., Nakamura, H., and Kondoh, H. (1997) Development 124, 1953–1962[Abstract]
  7. Aubury, S., and Charron, J. (2000) DNA Cell Biol. 19, 353–364[CrossRef][Medline] [Order article via Infotrieve]
  8. Fuchs, E., and Weber, K. (1994) Annu. Rev. Biochem. 63, 345–382[Medline] [Order article via Infotrieve]
  9. Spencer, V. A., Samuel, S. K., and Davie, J. R. (2000) Cancer Res. 60, 288–292[Abstract/Free Full Text]
  10. Hockfield, S., and McKay, R. D. (1985) J. Neurosci. 5, 3310–3328[Abstract]
  11. Frederiksen, K., and McKay, R. D. (1988) J. Neurosci. 8, 1144–1151[Abstract]
  12. Weggen, S., Bayer, T. A., Koch, A., Salewski, H., Scheidtmann, K. H., Pietsch, T., and Wiestler, O. D. (1997) Brain Pathol. 7, 731–739[Medline] [Order article via Infotrieve]
  13. Dahlstrand, J., Collins, P. V., and Lendahl, U. (1992) Cancer Res. 52, 5334–5341[Abstract/Free Full Text]
  14. Tohyama, T., Lee, V. M. Y., Rorke, L. B., Marvin, M., McKay, R. D., and Trojanowski, J. Q. (1992) Lab. Invest. 66, 303–313[Medline] [Order article via Infotrieve]
  15. Duggal, N., Schmidt-Kastner, R., and Antoine, H. M. (1997) Brain Res. 768, 1–9[CrossRef][Medline] [Order article via Infotrieve]
  16. Rutka, J., Ivanchuk, S., Mondal, S., Taylor, M., Sakai, K., Dirks, P., Jun, P., Jung, S., Beker, L. E., and Ackerley, C. (1999) Int. J. Dev. Neurosci. 17, 503–513[CrossRef][Medline] [Order article via Infotrieve]
  17. Flørenes, V. A., Holm, R., Myklebost, O., Lendahl, U., and Fodstad, O. (1994) Cancer Res. 54, 354–356[Abstract/Free Full Text]
  18. Reynolds, C. P., Biedler, J. L., Spengler, B. A., Reynolds, D. A., Ross, R. A., Frenkel, P., and Smith, R. G. (1986) J. Natl. Cancer Inst. 76, 375–387[Medline] [Order article via Infotrieve]
  19. Foley, J., Cohn, S. L., Salwen, H. R., Chagnovich, D., Cowen, J., Mason, K. L., and Parysek, L. M. (1991) Cancer Res. 51, 6338–6345[Abstract/Free Full Text]
  20. Wada, R. K., Seeger, R. C., Brodeur, G. M., Einhorn, P. A., Rayner, S. A., Tomayko, M. M., and Reynolds, C. P. (1993) Cancer 72, 3346–3354[CrossRef][Medline] [Order article via Infotrieve]
  21. Spengler, B. A., Lazarova, D. L., Ross, R. A., and Biedler, J. L. (1997) Oncol. Res. 9, 467–476[Medline] [Order article via Infotrieve]
  22. Lazarova, D. L., Spengler, B. A., Biedler, J. L., and Ross, R. A. (1999) Oncogene 18, 2703–2710[CrossRef][Medline] [Order article via Infotrieve]
  23. Ikegaki, N., Bukovsky, J., and Kennett, R. H. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 5929–5933[Abstract/Free Full Text]
  24. Messam, C. A., Hou, J., and Major, E. O. (2000) Exp. Neurol. 161, 585–596[CrossRef][Medline] [Order article via Infotrieve]
  25. Reis, L. F., Harada, H., Wolchok, J. D., Taniguichi, T., and Vilcek, J. (1992) EMBO J. 11, 185–193[Medline] [Order article via Infotrieve]
  26. Freshney, R. I. (1994) Culture of Animal Cells. A Manual of Basic Technique, 3rd. Ed., pp. 282–285, New York, Wiley-Liss, Inc., New York, NY
  27. Albini, A., Iwamoto, Y., Kleinman, H. C., Martin, G. R., Aaronson, S. A., Kozlowski, J. M., and McEwan, R. N. (1987) Cancer Res. 47, 3239–3245[Abstract/Free Full Text]
  28. Classon, M., Wennborg, A., Henriksson, M., and Klein, G. (1993) Gene (Amst.) 133, 153–161[CrossRef][Medline] [Order article via Infotrieve]
  29. Ferraro, A., Grandi, P., Eufemi, M., Altieri, F., Cervoni, L., and Turano, C. (1991) Biochem. Biophys. Res. Commun. 178, 1365–1370[CrossRef][Medline] [Order article via Infotrieve]
  30. Hildebrandt, A. L., and Neufer, P. D. (2000) Am. J. Physiol. 278, 1078–1086
  31. Zimmerman, L., Lendahl, U., Cunningham, M., McKay, R. D., Parr, B., Gavin, B., Mann, J., Vassileva, G., and McMahon, A. (1994) Neuron 12, 11–24[CrossRef][Medline] [Order article via Infotrieve]
  32. Cohn, S. L., Salwen, H. R., Quasney, M. W., Ikegaki, N., Cowan, J. M., Herst, C. V., Kennett, R. H., Rosen, S. T., DiGiuseppe, J. A., and Brodeur, G. M. (1990) Oncogene 5, 1821–1827[Medline] [Order article via Infotrieve]
  33. Dahlstrand, J., Zimmerman, L. B., McKay, R. D., and Lendahl, U. (1992) J. Cell Sci. 103, 589–597[Abstract]
  34. Lutz, W., Stohr, M., Schurmann, J., Lohr, A., and Schwab, M. (1996) Oncogene 13, 803–812[Medline] [Order article via Infotrieve]
  35. Shohet, J. M., Hicks, J. H., Plon, S. E., Burlingame, S. M., Stuart, S., Chen, S. Y., Brenner, M. K., and Nuchtern, J. G. (2002) Cancer Res. 62, 1123–1128[Abstract/Free Full Text]
  36. Sugiura, Y., Ma, L., Sun, B., Shimada, H., Lang, W., Seeger, R., and DeClerck, Y. (1999) Cancer Res. 59, 1327–1336[Abstract/Free Full Text]
  37. Grandori, C., and Eisenman, R. N. (1997) Trends Biochem. Sci. 22, 177–181[CrossRef][Medline] [Order article via Infotrieve]
  38. Lothian, C., and Lendahl, U. (1997) Eur. J. Neurosci. 9, 452–462[Medline] [Order article via Infotrieve]
  39. Thompson, E. W., Paik, S., Brunner, N., Sommers, C. L., Zugmaier, G., Clarke, R., Shima, T. B., Torri, J., Donahue, S., Lippman, M. E., Martin, G. R., and Dickson, R. B. (1992) J. Cell Physiol. 150, 534–544[CrossRef][Medline] [Order article via Infotrieve]
  40. Spencer, V. A., Coutts, A. S., Samuel, S. K., Murphy, L. C., and Davie, J. R. (1998) J. Biol. Chem. 273, 29093–29097[Abstract/Free Full Text]
  41. Thomas, S. K. (2003) Nestin Is a Potential Mediator of Malignancy in Human Neuroblastoma Cells. Ph.D. dissertation, New York, Fordham University
  42. Hendrix, M. J. (1996) Cancer Metastasis Rev. 15, 413–416[CrossRef][Medline] [Order article via Infotrieve]
  43. Hartig, R., Shoeman, R. L., Janetzko, A., Tolstonog, G., and Traub, P. (1998) J. Cell Sci. 111, 3573–3584[Medline] [Order article via Infotrieve]
  44. Wang, X., Tolstonog, G., Shoeman, R. L., and Traub, P. (1996) DNA Cell Biol. 15, 209–225[Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
X H Yang, Q L Wu, X B Yu, C X Xu, B F Ma, X M Zhang, S N Li, B T Lahn, and A P Xiang
Nestin expression in different tumours and its relevance to malignant grade
J. Clin. Pathol., April 1, 2008; 61(4): 467 - 473.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. M. Hansford, A. E. McKee, L. Zhang, R. E. George, J. T. Gerstle, P. S. Thorner, K. M. Smith, A. T. Look, H. Yeger, F. D. Miller, et al.
Neuroblastoma Cells Isolated from Bone Marrow Metastases Contain a Naturally Enriched Tumor-Initiating Cell
Cancer Res., December 1, 2007; 67(23): 11234 - 11243.
[Abstract] [Full Text] [PDF]

Home page
 J. Histochem. Cytochem.Home page
E. Bertelli, M. Regoli, L. Fonzi, R. Occhini, S. Mannucci, L. Ermini, and P. Toti
Nestin Expression in Adult and Developing Human Kidney
J. Histochem. Cytochem., April 1, 2007; 55(4): 411 - 421.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
I. Marzi, M. D'Amico, T. Biagiotti, S. Giunti, M. V. Carbone, D. Fredducci, E. Wanke, and M. Olivotto
Purging of the Neuroblastoma Stem Cell Compartment and Tumor Regression on Exposure to Hypoxia or Cytotoxic Treatment
Cancer Res., March 15, 2007; 67(6): 2402 - 2407.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
T. Biagiotti, M. D'Amico, I. Marzi, P. Di Gennaro, A. Arcangeli, E. Wanke, and M. Olivotto
Cell Renewing in Neuroblastoma: Electrophysiological and Immunocytochemical Characterization of Stem Cells and Derivatives
Stem Cells, February 1, 2006; 24(2): 443 - 453.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/27/27994    most recent
M312663200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomas, S. K.
Right arrow Articles by Ross, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomas, S. K.
Right arrow Articles by Ross, R. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement